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Male breast carcinoma (MBC) represents only 1% of all mammary
cancers (Hecht and Winchester, 1994) and seems to behave more
aggressively than female breast carcinomas (FBCs) (Ribeiro,
1985; Salvadori et al, 1994), although no difference in survival
between MBC and FBC has been reported (Guinee et al, 1993;
Cutuli et al, 1995; Weber-Chappuis et al, 1996). Treatment of
MBC is far from standardization because of the uncommon nature
of the disease, and no randomized comparisons of treatment have
been carried out as in FBC. Modified radical mastectomy and irra-
diation for cases with risk factors of local relapse and adjuvant
tamoxifen have been claimed as the optimal treatment in a large
series of patients with MBC (Cutuli et al, 1995).
Hormone receptor characterization of FBC is well established,
and the presence of oestrogen and progesterone receptors (ERs,
PGRs) suggests a tumour likely to respond to endocrine therapy
(Hähnel, 1985). ERs have also been extensively investigated in
MBC (Everson et al, 1980; Friedman et al, 1981; Dawson et al,
1992; Fox et al, 1992; Rogers et al, 1993; Pich et al, 1994, 1996;
Bruce et al, 1996; Joshi et al, 1996; Weber-Chappuis et al, 1996;
Williams et al, 1996; Willsher et al, 1997). The frequency of ER
expression is higher in MBC than FBC (Dawson et al, 1992;
Weber-Chappuis et al, 1996) and tamoxifen was reported to be a
useful adjuvant therapy in patients with advanced MBC (Bezwoda
et al, 1987; Ribeiro and Swindell 1992; Cutuli et al, 1995).
Few studies exist on the role of androgen receptors (ARs) in
breast cancer. Androgens cause regression of DMBA-induced
breast cancers in rats (Teller et al, 1966) and suppress growth in
human breast cancer cell lines (Poulin et al, 1988). ARs have been
detected in 31–91% FBCs (Allegra et al, 1979; Bryan et al, 1984;
Lea et al, 1989; Soreide et al, 1992; Isola, 1993; Kuenen-
Boumeester et al, 1996). No association was found with tumour
size, lymph node status (Allegra et al, 1979; Miller et al, 1985), or
tumour stage (Langer et al, 1990), although high AR levels seem
to predict lymph node metastases (Soreide et al, 1992). AR-posi-
tive patients respond better to hormone therapy (Nomura et al,
1980; Bryan et al, 1984; Birrell et al, 1995) and have longer
disease-free or overall survival rates (Bryan et al, 1984; Langer et
al, 1990; Birrell et al, 1995; Kuenen-Boumeester et al, 1996).
In only a few series of MBCs have ARs been investigated
(Calandra et al, 1984; Mercer et al, 1984; Pacheco et al, 1986;
Sasano et al, 1996). AR positivity ranged from 57% to 87%; a
direct relationship between AR and other steroid hormone recep-
tors was reported (Pacheco et al, 1986), although this was not
recently confirmed (Sasano et al, 1996). However, the number of
the patients is small (5–19), and no correlation with prognosis has
been reported so far.
In this work, we have retrospectively investigated the expres-
sion of ARs in 47 primary MBCs at diagnosis, using immuno-
histochemistry on sections from formalin-fixed, paraffin-embedded
tissues. The aim was to assess whether ARs were associated with
tumour clinicopathological features, ER and PGR, p53 protein
expression, cell proliferative activity and patient survival.
MATERIALS AND METHODS
Patients and tumours
Forty-seven MBCs were collected from the files of the pathology
sections of the Department of Biomedical Sciences and Human
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Summary Androgen receptor (AR) expression was retrospectively analysed in 47 primary male breast carcinomas (MBCs) using a
monoclonal antibody on formalin-fixed, paraffin-embedded tissues. AR immunopositivity was detected in 16 out of 47 (34%) cases. No
association was found with patient age, tumour stage, progesterone receptor (PGR) or p53 protein expression. Well-differentiated MBCs
tended to be AR positive more often than poorly differentiated ones (P = 0.08). A negative association was found between ARs and cell
proliferative activity: MIB-1 scores were higher (25.4%) in AR-negative than in AR-positive cases (21.11%; P = 0.04). A strong positive
association (P = 0.0001) was found between ARs and oestrogen receptors (ERs). In univariate analysis, ARs (as well as ERs and PGRs)
were not correlated with overall survival; tumour histological grade (P = 0.02), size (P = 0.01), p53 expression (P = 0.0008) and MIB-1 scores
(P = 0.0003) had strong prognostic value. In multivariate survival analysis, only p53 expression (P = 0.002) and histological grade (P = 0.02)
retained independent prognostic significance. In conclusion, the lack of association between AR and most clinicopathological features and
survival, together with the absence of prognostic value for ER/PGR status, suggest that MBCs are biologically different from female breast
carcinomas and make it questionable to use antihormonal therapy for patients with MBC.
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Italy), dating from 1967 to 1991. The mean age of the patients at
diagnosis was 61.5 years (27–86). All the patients were treated
with surgery: 42 received radical or modified radical mastectomy
and five simple mastectomy. Adjuvant post-operative radiation,
hormone (tamoxifen) or chemotherapy alone was administered
to 12, 4 and 3 patients respectively. Two patients received both
radiation and adjuvant hormone therapy, four radiation and
chemotherapy, three chemo- and hormone therapy, and four
chemo-, hormone and radiation therapy. A minimum follow-up of
4 years for surviving patients or to patient death was available for
all the cases. The mean follow-up time was 65 months (range
1–217 months). In each case, multiple samples were fixed in 10%
formalin and embedded in paraffin; haematoxylin–eosin, periodic
acid–Schiff, and Giemsa-stained sections were used for histology.
Carcinomas were classified according to the World Health
Organization (Scarff and Torloni, 1968) and pathologically staged
according to the International Union Against Cancer (Hermaneck
and Sobin, 1992). All were invasive ductal carcinomas; 14 were
stage pT1, 17 pT2 and 16 pT3 to 4; lymph node status was avail-
able in 33 cases: 13 were N0 and 20 N1–3. Histological grade was
assessed according to Elston and Ellis (1991): eight tumours were
grade 1, 27 grade 2, and 12 grade 3.
Androgen receptor staining and scoring
Sections (4 mm thick) on orthoaminosilane-coated slides
(Vectabond, Vector Laboratories, Burlingame, CA, USA), cut on
the day of immunostaining (freshly cut sections), were dewaxed,
rehydrated and brought to water. Endogenous peroxidase activity
was blocked by incubation for 5 min in 3% hydrogen peroxide.
Slides were placed in a glass box filled with 10 mmol l–1 citrate
buffer (pH 6.0) and subjected to microwave irradiation at 750 W
for three periods of 5 min each, with replacement of evaporated
buffer between periods of heating. The sections were then stained
with anti-AR monoclonal antibody (mAb) (clone 2F12)
(Novocastra, Newcastle, UK) at 1:10 dilution in 0.05% Tween 20
(Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS),
for 18 h at 4°C in a humidified atmosphere. A standard labelled
streptavidin biotin (LSAB) technique (Dakopatts, Glostrup,
Denmark) was used for visualization with diaminobenzidine as
chromogen. Slides were lightly counterstained with haematoxylin
and mounted in resin. Normal mouse serum was substituted for
primary antibody as a negative control. Freshly cut sections from
paraffin-embedded blocks of human hyperplastic prostate were
used as a positive control in each staining run. Scoring of AR
immunostaining was independently performed by two patholo-
gists (EM and AP), who had no knowledge of ER, PGR or other
clinicopathological data, using a standard light microscope
equipped with an ocular reticule (original magnification ´ 15) and
a ´ 40 objective. In each case, 1000 tumour cells were counted
from ten randomly selected areas, ensuring that the whole section
was scanned. All the reactive nuclei were considered positive,
regardless of the staining intensity, and the fraction of positive
cells was determined. The interobserver variation was less than
10%. A case was considered positive if more than 10% nuclei
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Table 1 AR expression in MBC according to clinicopathological features, ER/PGR status, p53 expression and cell proliferative activity
Variable n AR-positive cases (%) AR-negative cases (%) P-value
Whole series 47 16 (34) 31 (66)
Age (years)
≤ 45 6 2 (33.3) 4 (66.7)
46–70 25 9 (36) 16 (64) 0.95
> 70 16 5 (31.3) 11 (68.7)
Histological grade
G1 8 3 (37.5) 5 (62.5)
G2 27 12 (44.4) 15 (55.6) 0.08
G3 12 1 (8.3) 11 (91.7)
T-stage
pT1 14 6 (42.9) 8 (57.1)
pT2 17 6 (35.3) 11 (64.7) 0.58
pT3 or 4 16 4 (25) 12 (75)
N-stage
N0 13 5 (38.5) 8 (61.5)
N1–3 20 7 (35) 13 (65) 1
ER (%)
≤ 10 23 1 (4.3) 22 (95.7)
> 10 24 15 (62.5) 9 (37.5) 0.0001
PGR (%)
≤ 10 25 7 (28) 18 (72)
> 10 22 9 (40.9) 13 (59.1) 0.53
p53 immunoreactivity
Negative 20 6 (30) 14 (70)
Positive 27 10 (37) 17 (63) 0.84
MIB-1 scores (mean ± s.d.) 21.11 ± 4.7 25.4 ± 9.53 0.04a
aANOVA.were stained, according to the criterion most currently applied for
assessing ER or PGR immunopositivity on FBC sections.
ER, PGR, MIB-1 and p53 staining and scoring
Sections (4 mm thick) on poly-L-lysine-coated slides were stained
with specific mAbs using the LSAB method (Dakopatts) and
diaminobenzidine as chromogen. ER-ICA and PGR-ICA (Abbott
Laboratories, North Chicago, IL, USA) were used at kit dilution,
following the procedure of Hiort et al (1988). Normal mouse
serum was substituted for primary antibody as a negative control.
Sections from known ER-/PGR-positive FBCs were used as
positive controls. For MIB-1 and p53 staining, sections were
microwave pretreated for two periods of 5 min each in a glass box
filled with 10 mmol l–1 citrate buffer (pH 6.0) at 750 W. p53-
specific mAb DO7 (Oncogene Science, Uniondale, NY, USA), at
1:75 dilution and MIB-1 mAb (Immunotech, Marseille, France) at
1:100 dilution were then applied for 2 h at room temperature in a
humidified chamber. Sections of cases known to express p53
protein (i.e. high-grade FBCs) or MIB-1 (i.e. poorly differentiated
bladder carcinoma) were included in each staining run as positive
controls. All sections were independently scored by two patholo-
gists (EM and AP for ER/PGR; LC and AP for MIB-1 and p53)
following the same procedure reported for AR staining.
Statistical analysis
Associations between AR positivity/negativity and clinicopatho-
logical tumour features, ER/PGR status, and p53 expression were
assessed by the Yates-corrected chi-squared test. Association
between AR positivity/negativity and MIB-1 scores, considered as a
continuous variable, was evaluated by one-way analysis of variance
(ANOVA). Correlation between AR and ER was estimated by
Pearson’s correlation coefficient, when AR and ER scores were
considered as continuous variables. Univariate survival analysis
were based on Kaplan–Meier product-limit estimates of survival
distribution (Kaplan and Meier, 1958), and differences between
survival curves were tested using the generalized Wilcoxon test. The
relative importance of all the variables considered in the univariate
analysis was estimated using the Cox proportional hazards regres-
sion model (Cox, 1972). All data were processed with BioMeDical
computer Programs (BMDP) statistical software (programs 6D, 7D,
4F, 1L, 2L) (Dixon et al, 1990).
RESULTS
Distribution of AR immunoreactivity in MBCs
AR staining was exclusively nuclear with some variation in inten-
sity from cell to cell. Reaction intensity was generally weak, espe-
cially in very old archival material, and weaker than that observed
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Table 2 Correlation between clinicopathological features, hormone receptors, p53 expression and cell proliferative activity with survival in MBC
Variable n Median 5-year survival 10-year survival P-value
(months) rate (%) rate (%)
Whole series 47 60 50 18
Age (years)
≤ 45 6 22 33 0
46–70 25 77 64 27 0.12
> 70 16 52 35 14
Histological grade
G1 8 99 87 29
G2 27 57 51 26 0.02
G3 12 25 25 0
T-stage
pT1 14 96 85 26
pT2 17 38 34 21 0.01
pT3 or 4 16 25 37 16
N-stage
N0 13 77 62 26
N1–3 20 57 45 14 0.41
AR (%)
≤ 10 31 52 44 18
> 10 16 62 62 22 0.44
ER (%)
≤ 10 23 60 52 18
> 10 24 55 49 20 0.75
PGR (%)
≤ 10 25 73 59 21
> 10 22 52 41 16 0.76
p53 immunoreactivity
Negative 20 99 79 27
Positive 27 33 29 11 0.0008
MIB-1 scores
≤ 24 25 85 71 24
> 24 22 26 27 11 0.0003for ER/PGR staining in the same cases (Figures 1 and 2). In
normal ductal epithelium, weak AR immunopositivity was present
in almost all cells, stronger ER immunopositivity was evident in
many cells, and PGR immunostaining was present in only a few
cells (Figure 3 A–C). The percentage of AR-positive carcinoma
cells varied from 0% to 49.2% (mean 10.64%, s.d. ± 14.93%).
Sixteen tumours (34%) had more than 10% stained nuclei (posi-
tive cases); 31 (66%) had less than 10% stained nuclei (negative
cases). The mean percentage of AR-positive cells for the 16 cases
that were deemed positive was 29.24% (s.d. ± 10.73%; range
13.4–49.2%). Only 1 out of 16 cases (6.2%) had a percentage of
AR-positive cells (13.4%) near the cut-off value. Among the 14
cases collected up to January 1977, three (21.4%) were AR posi-
tive, whereas among the remaining 33 cases 13 (39.4%) were AR
positive. However, the difference between the old archived
samples and the more recent ones was not significant (P = 0.39).
Association of AR with clinicopathological features,
ER/PGR status, p53 and MIB-1 immunoreactivity
No association was found between AR immunopositivity and
patient age, tumour stage, PGR and p53 overexpression. A trend
towards association was found for histological grade: 37.5% grade 1
and 44.4% grade 2 carcinomas were AR positive, whereas only
8.3% grade 3 were positive (P = 0.08). A strong association was
seen between AR and ER status: 15 out of 16 AR-positive cases
were also ER positive, and 22 out of 31 AR-negative cases were also
ER negative (P = 0.0001). AR and ER were linearly correlated (r =
0.51, P < 0.001). A weak negative association was detected between
AR and cell proliferative activity: the mean percentage of MIB-1
positive cells was 25.4% in AR negative compared with 21.11% in
AR-positive cases (P = 0.04). The results are listed in Table 1.
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Figure 1 Immunocytochemical detection of AR in MBC. The intensity of the
reaction is rather weak and shows some variation from nucleus to nucleus
(AR immunoperoxidase, haematoxylin counterstain, magnification ´ 260)
Figure 2 Immunocytochemical detection of ER in a consecutive serial
section of the case illustrated in Figure 1. Most neoplastic cells react more
intensely and uniformly than observed for AR staining (ER-ICA
immunoperoxidase, haematoxylin counterstain, magnification ´ 260)
Figure 3 Immunocytochemical detection of AR (A), ER (B) and PGR (C) in
consecutive serial sections of a normal duct of male breast. A weak AR
reaction is present in almost all epithelial cells; a stronger ER reaction is
seen in many epithelial cells; PGR immunoreactivity is present in only a few
nuclei (LSAB, ER-ICA and PGR-ICA immunoperoxidase, haematoxylin
counterstain, magnification ´ 260)Univariate survival analysis
At the time of analysis, 36 patients (76.6%) had died of the disease
and 11 (23.4%) were alive. The mean follow-up for surviving
patients was 114 months (median 102, range 48–217). The median
survival for the whole series was 60 months (1–217). The overall
5- and 10-year survival rates were 50% and 18% respectively. AR
expression was not associated with survival: the median survival
was 52 months for AR-negative compared with 62 months for AR-
positive cases (P= 0.44). Also, no association was found for ER,
PGR and lymph node status. A trend for significance was found
for age: patients younger than 45 years or older than 70 had
a shorter survival than middle-aged men (P= 0.12). Histological
grade (P= 0.02), tumour size (P= 0.01), MIB-1 scores (P= 0.0003)
and p53 immunoreactivity (P= 0.0008) had strong prognostic
value. The results are listed in Table 2.
Multivariate survival analysis
Multivariate survival analysis, performed by testing the association
of all variables considered in the univariate analysis in the Cox
model, showed that only p53 immunoreactivity (c2 = 9.59; P=
0.002; hazard ratio 2.71) and histological grade (c2 = 5.23; p = 0.02;
hazard ratio 1.86) retained independent prognostic significance.
DISCUSSION
Androgen receptors were detected in 34% MBCs; this rate is far
lower than that (57–87%) reported in smaller series of MBCs by
other investigators (Calandra et al, 1984; Mercer et al, 1984;
Pacheco et al, 1986; Sasano et al, 1996). The discrepancy may be
due in part to the different methodologies used for AR demonstra-
tion; indeed, most investigators (Calandra et al, 1984; Mercer et al,
1984; Pacheco et al, 1986) performed AR assay from cytosol
preparations, which cannot discriminate between receptor-
containing malignant and non-malignant cells, or used polyclonal
antibodies to detect AR both in neoplastic and stromal cells
(Sasano et al, 1996). We performed immunohistochemistry on
formalin-fixed, paraffin-embedded tissues, using a monoclonal
antibody; with the same procedure, Isola (1993) could not
demonstrate AR in routinely fixed material despite testing several
antigen unmasking techiques; furthermore, we evaluated AR
immunopositivity only in neoplastic cells.
ER and PGR can be reliably assessed on formalin-fixed, paraffin-
embedded tissues, with results comparable to those obtained using
cytosol assays or frozen-sections (Wilbur et al, 1992; Pertschuk
et al, 1996); however, diminished immunoreactivity over time in
paraffin-embedded sections stored on glass slides at room tempera-
ture has recently been observed during evaluation of several anti-
gens in breast carcinoma (Prioleau and Schnitt, 1995). A significant
loss of staining intensity for ER protein occurred on slides stored at
room temperature for 12 weeks (Jacobs et al, 1996). In our study,
immunohistochemistry for AR was performed the same day of
cutting, and we believe that this technique reveals the actual AR
status of MBCs. The reliability of the method is also supported by
the association between AR and ER (chi-squared 15.19, P= 0.0001)
or by the linear relationship between AR and ER scores (r0.51,
P< 0.001) found in the present series. These results are in accor-
dance with most studies showing association between AR and ER in
FBCs (Allegra et al, 1979; Miller et al, 1985; Soreide et al, 1992;
Isola, 1993) or MBCs (Pacheco et al, 1986).
We found no significant association between AR and age, in
line with a few reports on FBC (Allegra et al, 1979; Bryan et al,
1984; Miller et al, 1985), nor did we find any association with
tumour size or lymph node status, in accordance with similar
results on FBCs (Allegra et al, 1979; Miller et al, 1985; Langer et
al, 1990). A trend towards association (P= 0.08) was observed for
histological grade: 42.8% G1 or 2 cases, but only 8.3% G3 were
AR positive, in agreement with studies on FBCs showing that
hormone receptors are expressed at higher rates in well-differenti-
ated tumours (Millis, 1980; Walker et al, 1988).
A weak but significant association could be seen between AR
and cell proliferative activity; indeed, AR-negative cases had higher
MIB-1 scores (25.4%) than AR-positive cases (21.11%; P= 0.04),
in accordance with Isola (1993) who showed that FBCs with low
S-phase fraction were more often AR positive than rapidly pro-
liferating ones. Our findings are also in agreement with the well-
known negative association between ER/PGR and cell proliferation
reported in most FBCs (Bertuzzi et al, 1981; Gerdes et al, 1987). No
correlation was found between AR expression and patient survival.
However, the role of ARs as prognostic factors is still controversial
in FBC: AR-positive cases have been associated with better prog-
nosis in some series (Bryan et al, 1984; Langer et al, 1990; Birrell
et al, 1995), but AR status did not provide significant prognostic
information on relapse-free survival in another large series (Soreide
et al, 1992) and did not appear to be an independent variable in
multivariate analysis (Kuenen-Boumeester et al, 1996).
Finally, we did not find any prognostic significance for ER/PGR
status. This confirms our previous reports in smaller series of
MBCs (Pich et al 1994, 1996), but contrasts with the well-known
prognostic value of ER/PGR detection in FBC (Alanko et al, 1985;
McGuire and Clark, 1985; Pertschuck et al, 1990). We are aware
that the number of cases in the present series is relatively small; a
larger series would probably have enough power to reveal other
weak prognostic factors.
Recently, it was shown that ER and PGR are more expressed in
MBC than FBC (Dawson et al, 1992; Weber-Chappuis et al, 1996),
but the proteins under oestrogen control (such as pS2, heat shock
protein 27 and cathepsin D) are more frequent in FBC than MBC
suggesting that ERs in MBC do not have the same function as in
FBC (Weber-Chappuis et al, 1996). This could also explain the
variable success reported for antihormonal treatment of MBC
(Everson et al, 1980; Bezwoda et al, 1987).
In conclusion, lack of association between AR and most clinico-
pathological tumour features, and lack of correlation between AR,
ER and PGR status with patient survival found in the present
series, together with the side-effects of tamoxifen administration
reported in MBC (Anelli et al, 1994), make questionable the use of
antihormonal therapy for patients with MBC.
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